Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naïve Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study.
暂无分享,去创建一个
Christina Hulsbergen-van de Kaa | Jeroen Veltman | M. Rovers | A. Padhani | J. Barentsz | G. Hannink | P. Zamecnik | J. Veltman | B. Israël | M. Hoogenboom | I. V. van Oort | Jelle O Barentsz | Anwar R Padhani | Marloes van der Leest | Erik Cornel | Bas Israël | Rianne Hendriks | Martijn Hoogenboom | Patrik Zamecnik | Dirk Bakker | Anglita Yanti Setiasti | Huib van den Hout | Hans van der Lelij | Inge van Oort | Sjoerd Klaver | Frans Debruyne | Michiel Sedelaar | Gerjon Hannink | Maroeska Rovers | E. Cornel | M. Sedelaar | S. Klaver | R. Hendriks | M. V. D. van der Leest | F. Debruyne | C. Hulsbergen–van de Kaa | M. M. van der Leest | H. van den Hout | Hans van der Lelij | Dirk Bakker | P. Zámecnik
[1] Lorenzo Farina,et al. Prostate cancer screening research can benefit from network medicine: an emerging awareness , 2020, npj Systems Biology and Applications.
[2] Saila Kauppila,et al. Prebiopsy Multiparametric Magnetic Resonance Imaging for Prostate Cancer Diagnosis in Biopsy-naive Men with Suspected Prostate Cancer Based on Elevated Prostate-specific Antigen Values: Results from a Randomized Prospective Blinded Controlled Trial. , 2016, European urology.
[3] C. Catalano,et al. Multiparametric magnetic resonance imaging vs. standard care in men being evaluated for prostate cancer: a randomized study. , 2015, Urologic oncology.
[4] P. Acher,et al. Clinical utility and cost modelling of the phi test to triage referrals into image-based diagnostic services for suspected prostate cancer: the PRIM (Phi to RefIne Mri) study , 2020, BMC Medicine.
[5] A. L. Linares Quevedo,et al. Prospective nonrandomized study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy to magnetic resonance imaging with subsequent MRI-guided biopsy in biopsy-naïve patients. , 2017, Minerva urologica e nefrologica = The Italian journal of urology and nephrology.
[6] S. Dason,et al. A novel biparametric magnetic resonance imaging sequence provides a more efficient and similarly efficacious method of risk stratifying men clinically suspected of having prostate cancer. , 2019, Translational andrology and urology.
[7] Maarten de Rooij,et al. Cost-effectiveness of magnetic resonance (MR) imaging and MR-guided targeted biopsy versus systematic transrectal ultrasound-guided biopsy in diagnosing prostate cancer: a modelling study from a health care perspective. , 2014, European urology.
[8] J. Hugosson,et al. Role of Magnetic Resonance Imaging in Prostate Cancer Screening: A Pilot Study Within the Göteborg Randomised Screening Trial. , 2016, European urology.
[9] Christina Hulsbergen-van de Kaa,et al. Results of Targeted Biopsy in Men with Magnetic Resonance Imaging Lesions Classified Equivocal, Likely or Highly Likely to Be Clinically Significant Prostate Cancer. , 2017, European urology.
[10] K. Gwet. Computing inter-rater reliability and its variance in the presence of high agreement. , 2008, The British journal of mathematical and statistical psychology.
[11] H. G. van der Poel,et al. What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel. , 2017, European urology.
[12] Baris Turkbey,et al. Multiparametric prostate magnetic resonance imaging in the evaluation of prostate cancer , 2016, CA: a cancer journal for clinicians.
[13] A. D'Amico,et al. American Cancer Society Guideline for the Early Detection of Prostate Cancer: Update 2010 , 2010, CA: a cancer journal for clinicians.
[14] N. Lumen,et al. What kind of prostate cancers do we miss on multiparametric magnetic resonance imaging? , 2016, European Radiology.
[15] F. Montorsi,et al. Active Surveillance for Low-risk Prostate Cancer: The European Association of Urology Position in 2018. , 2018, European urology.
[16] Katarzyna J Macura,et al. Synopsis of the PI-RADS v2 Guidelines for Multiparametric Prostate Magnetic Resonance Imaging and Recommendations for Use. , 2016, European urology.
[17] B. Hadaschik,et al. Multicentre evaluation of magnetic resonance imaging supported transperineal prostate biopsy in biopsy‐naïve men with suspicion of prostate cancer , 2018, BJU international.
[18] Yair Lotan,et al. Systematic review of complications of prostate biopsy. , 2013, European urology.
[19] B. Delahunt,et al. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System , 2015, The American journal of surgical pathology.
[20] M. Parmar,et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confi rmatory study , 2018 .
[21] Baris Turkbey,et al. Prostate Imaging-Reporting and Data System Steering Committee: PI-RADS v2 Status Update and Future Directions. , 2019, European urology.
[22] A. Ouzzane,et al. MRI in addition to or as a substitute for prostate biopsy: the clinician's point of view. , 2012, Diagnostic and interventional imaging.
[23] F. Schröder,et al. Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies. , 2014, European urology.
[24] Katarzyna J Macura,et al. Reply to Erik Rud and Eduard Baco's Letter to the Editor re: Re: Jeffrey C. Weinreb, Jelle O. Barentsz, Peter L. Choyke, et al. PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2. Eur Urol 2016;69:16-40. , 2016, European urology.
[25] D. Margolis,et al. PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2. , 2016, European urology.
[26] H. G. van der Poel,et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. , 2017, European urology.
[27] R. Faletti,et al. Diagnostic Pathway with Multiparametric Magnetic Resonance Imaging Versus Standard Pathway: Results from a Randomized Prospective Study in Biopsy-naïve Patients with Suspected Prostate Cancer. , 2017, European urology.
[28] T. H. van der Kwast,et al. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. , 2014, European urology.
[29] Marta O. Soares,et al. Optimising the Diagnosis of Prostate Cancer in the Era of Multiparametric Magnetic Resonance Imaging: A Cost-effectiveness Analysis Based on the Prostate MR Imaging Study (PROMIS) , 2018, European urology.
[30] H. Merisaari,et al. Prediction of prostate cancer aggressiveness using 18F-Fluciclovine (FACBC) PET and multisequence multiparametric MRI , 2020, Scientific Reports.
[31] L. Hooft,et al. Comparing Three Different Techniques for Magnetic Resonance Imaging-targeted Prostate Biopsies: A Systematic Review of In-bore versus Magnetic Resonance Imaging-transrectal Ultrasound fusion versus Cognitive Registration. Is There a Preferred Technique? , 2017, European urology.
[32] Baris Turkbey,et al. Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. , 2015, JAMA.
[33] D. Margolis,et al. MRI‐Targeted or Standard Biopsy for Prostate‐Cancer Diagnosis , 2018, The New England journal of medicine.
[34] A. Sidana,et al. Risk of Upgrading from Prostate Biopsy to Radical Prostatectomy Pathology—Does Saturation Biopsy of Index Lesion during Multiparametric Magnetic Resonance Imaging‐Transrectal Ultrasound Fusion Biopsy Help? , 2017, The Journal of urology.
[35] B. Bodelle,et al. Complication Rates After TRUS Guided Transrectal Systematic and MRI-Targeted Prostate Biopsies in a High-Risk Region for Antibiotic Resistances , 2020, Frontiers in Surgery.
[36] F. Giganti,et al. MRI in prostate cancer diagnosis: do we need to add standard sampling? A review of the last 5 years , 2018, Prostate Cancer and Prostatic Diseases.
[37] C. Catalano,et al. Negative Multiparametric Magnetic Resonance Imaging for Prostate Cancer: What's Next? , 2018, European urology.
[38] I. Balslev,et al. Assessment of the Diagnostic Accuracy of Biparametric Magnetic Resonance Imaging for Prostate Cancer in Biopsy-Naive Men , 2018, JAMA network open.